Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 3, 2003, Pages 210-216

  Brewer, George J ^a,b   Ullenbruch, Matthew R ^a   Dick, Robert ^a   Olivarez, Leovigildo ^a   Phan, Sem H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BLEOMYCIN; CERULOPLASMIN; CYTOKINE; TETRATHIOMOLYBDIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CERULOPLASMIN BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; DOSE RESPONSE; FEMALE; FIBROSIS; HISTOPATHOLOGY; LUNG FIBROSIS; MOUSE; NONHUMAN; WEIGHT REDUCTION;

EID: 0037342259     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2003.20     Document Type: Article

References (27)

1. Coker RK, Laurent GJ. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax 1997;52:294-6.
2. Zhang K, Phan SH. Cytokines and pulmonary fibrosis. Biol Signals Recept 1996;5:232-9.
3. Phan SH. New strategies for treatment of pulmonary fibrosis. Thorax 1995;50:415-21.
4. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lucacs NW, et al. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol 1995;57:782-7.
5. Hogaboam CM, Smith RE, Kunkel SL. Dynamic interactions between lung fibroblasts and leukocytes: implications for fibrotic lung disease. Proc Assoc Am Phys 1998;110:313-20.
6. Khalil N, Greenberg AH. The role of TGF-beta in pulmonary fibrosis. Ciba Found Syrup 1991;157:194-211.
7. Border WA, Noble NA. Mechanisms of disease: transforming growth factor (beta) in tissue fibrosis. N Engl J Med 1994;331:1286-92.
8. Denis M. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology 1994;82:584-90.
9. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, et al. Connective tissue growth factor mRNA expression is unregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998;275:L365-71.
10. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
11. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor): expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999;21:693-700.
12. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huang X, et al. TGF-β is critical mediator of acute lung injury. J Clin Invest 2001;107:1537-44.
13. Ishizuka M, Takayama H, Takeuchi T, Umezawa H. Activity and toxicity of bleomycin. J Antibiot (Tokyo) 1967;20:15.
14. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992;18:29-43.
15. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, and antiangiogenic agent: phase I study. Clin Cancer 2000;6:1-10.
16. Merajver SD, Irani J, Van Golen K, Brewer GJ. Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice. Proceedings of the American Association for Cancer Research Conference on Angiogenesis and Cancer, Saginaw, MI, B11, 1998.
17. Khan MK, Miller MW, Taylor J, Navkiranjit KG, Dick RD, Val Golen K, et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002;4:1-7.
18. Cox CD, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701.
19. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from Wilson's disease. Exp Biol Med 2001;226:665-73.
20. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of 0-dianisidine dihydrochloride. Clin Chem 1974;20:1556-63.
21. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, Phan SH. The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1998;64:657-66.
22. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-β1 in mesangial cells. J Leukoc Biol 1999;22:32145-52.
23. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 1999;277:L628-35.
24. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994;125:929-43.
25. Gallagher JT. Heparin sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61.
26. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK. Brunberg JA. Treatment of Wilson's disease with ammonium tetrathiomolybdate: II initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch Neurol 1996;53:1017-25.
27. Brewer GJ. Recognition, diagnosis and management of Wilson's disease. Proc Soc Exp Biol Med 2000;223:39-46.